Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar 608002, Tamil Nadu, India.
Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar 608002, Tamil Nadu, India.
Eur J Pharmacol. 2014 Nov 15;743:117-25. doi: 10.1016/j.ejphar.2014.09.010. Epub 2014 Sep 17.
Hypertension is one of the main factors causing cardiovascular diseases. The present study was designed to evaluate the protective effect of vanillic acid against nitric oxide deficient rats. Hypertension was induced in adult male albino rats of Wistar strain, weighing 180-220g, by oral administration of N(ω)-nitro-l arginine methyl ester (l-NAME) 40mg/kg in drinking water for 4 weeks. Vanillic acid was administered orally at a dose of 50mg/kg b.w. Nitric oxide deficient rats showed increased levels of mean arterial pressure (MAP), heart rate (HR) and decreased heart nitric oxide metabolites (NOx). A significant increase in the levels of plasma cholesterol, low density lipoprotein-cholesterol (LDL-C), very low density lipoprotein-cholesterol (VLDL-C), triglycerides (TG), free fatty acids (FFA), phospholipids (PL), 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA) reductase in the plasma, liver and kidney and decreased level of high density lipoprotein-cholesterol (HDL-C) are observed, whereas there is a decrease in the activities of plasma lipoprotein lipase (LPL) and lecithin cholesterol acyl transferase (LCAT) in nitric oxide deficient rats. l-NAME rats also showed an increase in TC, TG, FFA and PL levels in the liver and kidney tissues. Vanillic acid treatment brought the above parameters towards near normal level. Moreover the down regulated endothelial nitric oxide synthase (eNOS) and up regulated expression of endothelin 1 (ET1) components was also attenuated by vanillic acid treatment. All the above outcomes were confirmed by the histopathological examination. These results suggest that vanillic acid has enough potential to attenuate hypertension, dyslipidemia and hepatic and renal damage in nitric oxide deficient rats.
高血压是引起心血管疾病的主要因素之一。本研究旨在评估香草酸对一氧化氮缺乏大鼠的保护作用。通过在饮用水中口服 N(ω)-硝基-L-精氨酸甲酯 (l-NAME)40mg/kg,将成年雄性白化 Wistar 大鼠诱导为高血压,持续 4 周。香草酸以 50mg/kg b.w.的剂量口服给药。一氧化氮缺乏大鼠的平均动脉压 (MAP)、心率 (HR) 升高,心脏一氧化氮代谢物 (NOx) 降低。血浆胆固醇、低密度脂蛋白胆固醇 (LDL-C)、极低密度脂蛋白胆固醇 (VLDL-C)、甘油三酯 (TG)、游离脂肪酸 (FFA)、磷脂 (PL)、3-羟-3-甲基戊二酰辅酶 A (HMG-CoA) 还原酶水平显著升高,高密度脂蛋白胆固醇 (HDL-C) 水平降低,而血浆脂蛋白脂肪酶 (LPL) 和卵磷脂胆固醇酰基转移酶 (LCAT) 的活性降低。一氧化氮缺乏大鼠的肝和肾组织中也观察到 TC、TG、FFA 和 PL 水平升高。香草酸治疗使上述参数接近正常水平。此外,香草酸治疗还减弱了下调的内皮型一氧化氮合酶 (eNOS) 和上调的内皮素 1 (ET1) 表达。所有上述结果均通过组织病理学检查得到证实。这些结果表明,香草酸具有足够的潜力减轻一氧化氮缺乏大鼠的高血压、血脂异常以及肝和肾损伤。